Home › Ductal Carcinoma In Situ (DCIS) › NCT05218044

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* DCIS spanning 2 cm or less based on its radiographic appearance by mammography and/or breast contrast-enhanced MRI
* Diagnosis of DCIS by minimally invasive needle biopsy
* No prior history of DCIS or invasive breast cancer in the same breast
* No history of surgical biopsy and/or lumpectomy for diagnosis/treatment in the same breast
* Adequate breast volume and skin clearance to permit cryoablation as assessed by Dr. Holmes. This excludes male and females with breasts too small to allow safe cryoablation
* Non-pregnant, non-lactating, and no history of pregnancy within the preceding 6 months
* No history of breast radiation in the same breast

About the study

Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation zone of necrosis.

What is being tested

• Cryoablation (procedure)

Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale · Participants: 30 · Started: Nov 1, 2021

Contact the study team

• Dennis R Holmes, M.D. · Phone: 800-203-5515

Official record on ClinicalTrials.gov — NCT05218044

Locations in the U.S.

Conditions

• Ductal Carcinoma In Situ (DCIS)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.